4de Mendonca A,Vincent JL,Suter PM,et al.Acute renal failure in the ICU:risk factors and outcome evaluated by the SOFA score.Intensive Care Med,2000,26:915-921.
5Lia(n)o F,Junco E,Pascual J,et al.The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings.Kidney Int Suppl,1998,66:S16-24.
8Chertow GM,Soroko SH,Paganini EP,et al.Mortality after acute renal failure:models for prognostic stratification and risk adjustment.Kidney Int,2006,70:1120-1126.
9Hoste EA,Kellum JA.Acute renal failure in the critically ill:impact on morbidity and mortality.Contrib Nephrol,2004,144:1-11.
10Hoste EA,Kellum JA.RIFLE criteria provide robust assessment of kidney dysfunction and correlate with hospital mortality.Crit Care Med,2006,34:2016-2017.
二级参考文献9
1Ahlstrom A.Tallgren M.Peltonen S.et al.Evolution and predictive power of serum cystatin C in acute renal failure.Clin Nephrol.2004.62(5):344-350.
2Christensson AG, Grubb AO, Nilsson JA, et al. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med. 2004, 256 (6): 510-518.
3Li FK, Ho SK, Yip TP, et al. Cystatin C assay for the detection of renal dysfunction in Chinese renal transplant recipients. Clin Chim Acta, 2002,322 (1-2): 133-137.
4Kazama JJ, Kutsuwada K, Ataka K, et al. Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron, 2002,91 (1): 13-20.
5Bellomo R, Ronco C, Kellum JA, et all. Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Ouality Initiative (ADQI)Group. Crit Care. 2004, 8 (4): R204-R212.
7Filler G.Bokenkamp A.Hofmam W,et al.Cystatin C as a marker of GFR-history.indieations.and future research.Clin Biochem.2005.38(1):1-8.
8Dharnidharka VR.Kwon C.Stevens G.Serum cystatin C is superior to serum creatinine as a marker of kidney function:a meta-analysis.Am J Kidney Dis.2002.40(2):221-226.
